Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Achieve Life Sciences (ACHV) Cash & Equivalents (2016 - 2026)

Achieve Life Sciences (ACHV) has disclosed Cash & Equivalents for 17 consecutive years, with $29.3 million as the latest value for Q1 2026.

  • Quarterly Cash & Equivalents rose 26.29% to $29.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $29.3 million through Mar 2026, up 26.29% year-over-year, with the annual reading at $20.9 million for FY2025, 64.11% up from the prior year.
  • Cash & Equivalents for Q1 2026 was $29.3 million at Achieve Life Sciences, up from $20.9 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $66.4 million in Q1 2024, with the low at $12.8 million in Q4 2024.
  • Average Cash & Equivalents over 5 years is $31.4 million, with a median of $25.1 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents surged 420.4% in 2024, then plummeted 65.06% in 2025.
  • Achieve Life Sciences' Cash & Equivalents stood at $22.8 million in 2022, then tumbled by 37.37% to $14.3 million in 2023, then dropped by 10.52% to $12.8 million in 2024, then surged by 64.11% to $20.9 million in 2025, then soared by 40.0% to $29.3 million in 2026.
  • Per Business Quant, the three most recent readings for ACHV's Cash & Equivalents are $29.3 million (Q1 2026), $20.9 million (Q4 2025), and $48.1 million (Q3 2025).